It’s been announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID-19 treatment for use in the UK.
Following a rigorous review of its safety, quality, and effectiveness by the UK regulator and the government’s independent expert scientific advisory body, the Commission on Human Medicines, the treatment was found to successfully reduce the risk of hospitalisation and death in people with mild to moderate COVID-19 infection, who are at an increased risk of developing severe disease.
The treatment – known as Xevudy (sotrovimab) – has been developed by GSK and Vir Biotechnology, and is a single monoclonal antibody that, according to a statement published by the UK government website, works by binding to the spike protein on the outside of the COVID-19 virus.
This in turn prevents the virus from attaching to and entering human cells, so that it cannot replicate in the body.
Xevudy is the second monoclonal antibody therapeutic to be approved, following Ronapreve.
ADVERTISEMENT
In a clinical trial, a single dose of the monoclonal antibody was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection, and based on the clinical trial data, the government says sotrovimab is most effective when taken during the early stages of infection.
And so, the MHRA has said it recommends its use as soon as possible and within five days of symptom onset.
ADVERTISEMENT
BREAKING NEWS:
A new treatment against COVID-19 has been approved by @MHRAgovuk.
We'll closely monitor how effective Xevudy is against the Omicron variant and will work on deployment plans with the NHS.https://t.co/ZilAKtwdaO
The approval for use of this treatment follows the confirmation that the first pill to treat symptomatic COVID-19 – molnupiravir – has also been approved for use in the UK back at the start of November.
Like molnupiravir, Xevudy has been authorised for use in people who have mild to moderate COVID-19 infection, and at least one risk factor for developing severe illness – such as obesity, older age (+60 years), diabetes mellitus, or heart disease – but unlike molnupiravir, sotrovimab is administered by intravenous infusion over 30 minutes, and it has also been approved for individuals aged 12 and above who weigh more than 40kg.
ADVERTISEMENT
The MHRA says it’s too early to know whether the Omicron variant has any impact on sotrovimab’s effectiveness, but the body will work with the company to establish this.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID-19 treatment for use in the UK / Credit: Pixabay
“I am pleased to say that we now have another safe and effective COVID-19 treatment, Xevudy (sotrovimab), for those at risk of developing severe illness,” announced Dr June Raine, Chief Executive of the MHRA.
“This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19, and signals another significant step forward in our fight against this devastating disease.
“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA have conducted a robust and thorough assessment of all the available data.”
Featured Image – Flickr
News
Arrest made after 14-year-old boy found in critical condition on Market Street
Daisy Jackson
An arrest has been made after a teenage boy was found unresponsive on Market Street in Manchester city centre.
Detectives believe that the boy, 14, was approached by seven males who stole a designer jacket from him.
Following the altercation, he went into cardiac arrest and was rushed to hospital in a critical condition.
Thankfully, the teenager is continuing to recover well.
Detectives from Manchester City Centre Criminal Investigation Department confirmed that an 18-year-old male was arrested yesterday, Thursday 20 February.
He has been arrested on suspicion of robbery and remains in police custody.
Detective Inspector Mark Astbury of GMP’s City Centre Criminal Investigation Department, said: “We hope the victim can continue his recovery following what must have been a terrifying ordeal for him.
“Officers are fully investigating all aspects of this shocking incident that has left a man with serious injuries in hospital.
“Our work doesn’t stop here, we are continuing to investigate this incident and information from the public plays an incredibly important role in our investigations and I ask that the community keep talking to us and keep sharing their concerns with us so our teams can act.”
If you have any information, contact GMP 101 or 0161 856 4305 quoting log 2854 of 16/2/25.
Comedy is being prescribed instead of antidepressants as part of UK trials
Emily Sergeant
Trials are currently underway to see if comedy could be an alternative to antidepressants as a way to reduce NHS costs.
UK tech company Craic Health has secured important funding for its ‘comedy on prescription’ project that’s aimed at helping the Government work with the comedy industry, communities, and organisations on comedy-based social prescriptions in the hope that they can solve financial struggles within the NHS.
The groundbreaking scheme uses stand-up shows and workshops to help people who are isolated, lonely, and vulnerable.
Craic believes comedy is an ‘untapped opportunity’ to improve health and wellbeing, and has a goal to make comedy easier to access, so that it can help communities experience its mental health and social benefits.
To achieve this, the company has started trialling Comedy-on-Prescription experiences in the UK – starting in London, with the potential for expansion – which includes things like curated comedy panel game show events and workshops, and general stand-up comedy shows at some of the capital’s world-famous venues.
Comedy is being prescribed instead of antidepressants as part of UK trials / Credit: Wikimedia Commons
“Mental health issues like loneliness, isolation, and stress are more common than ever,” the company explains.
“So much so that it’s projected that by 2030, mental health problems, particularly depression, will be the leading cause of mortality and morbidity globally, [but] in this challenging world, comedy stands out as a universal language that breaks barriers.
“Research shows that comedy and laughter have powerful effects – they bring people together, create positive connections, and make life more enjoyable.”
Craic Health says that social prescribing, of which Comedy-on-Prescription is a part of, is all about inclusivity, which makes it making it suitable for people of all ages, backgrounds, and abilities.
Its focus is on personalised support, tailored to individual needs and preferences.
The Manc -
2nd December 2021 
